Pharma major, Lupin’s subsidiary, Lupin Pharmaceuticals Inc, has launched its Fenofibrtae tablets, 48 mg and 145 mg strengths in the United States. The company has earlier received final approval for the same from the US Food and Drug Administration (USFDA).
Lupin’s Fenofibrtae tablets are the AB rated generic equivalent of Abbott’s TRICOR tablets and are indicated for primary Hypercholesterolemia or Mixed Dyslipidemia and Severe Hypertriglyceridemia. Abbott’s TRICOR tablets 48 mg and 145 mg had sales of $1.26 billion as per IMS Health, June, 2012.
Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: